author-photo

Alain Vergnenègre

57

Papers

5688

Citations

Citation Trend

Filter By

Papers (40) Sort By

Journal Conference Others

Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax Risk.

2021 International Journal of Chronic Obstructive Pulmonary Disease
Show All
- Source
- Cite
- Save
Citations (0)
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis:

2021 Therapeutic Advances in Medical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
Perceptions et connaissances sur le cancer du poumon en France : une enquête en regards croisés auprès du grand public et des médecins

2020 Revue des Maladies Respiratoires Actualités
Show All
- Source
- Cite
- Save
Citations (0)
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC‡ 04-2017)

2020 Future Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Economic analyses of immune-checkpoint inhibitors to treat lung cancer.

2020 Expert Review of Pharmacoeconomics & Outcomes Research
- Alain Vergnenègre
- Christos Chouaïd
Show All
- Source
- Cite
- Save
Citations (0)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (17)
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

2020 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (206)
O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (4)
Angiogenesis inhibitor plus erlotinib versus erlotinib alone as first-line for advanced non-small cell lung-cancer harboring EGFR mutation.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)